Curated SPACs News
Acquisition will strengthen Landmarks Illinois’ commitment to fostering community-driven preservation and economic development across the state
Edmonton, Alberta, Canada, Oct. 07, 2026 (GLOBE NEWSWIRE) — FOR IMMEDIATE RELEASE
Local philanthropist Leslie Bissett’s gift will mean Calgary receives state-of-the-art equipment primed to bolster women’s cardiovascular care
Acquisition adds high-voltage transformer, breaker, and portable substation capabilities to the IPS Electrification platform
Defense, space firms turn to SPACs as investor appetite soars Reuters
ATHENS, Greece, Oct. 07, 2026 (GLOBE NEWSWIRE) — TOP Ships Inc. (the “Company” or “TOP Ships”) (NYSE American: TOPS), an international owner and operator of modern, fuel-efficient “ECO” tanker vessels, announced today that it has entered into a share purchase agreement with a related party (the “Seller”) to purchase the shares of four companies (the “SPVs”) which have entered into shipbuilding contracts with Guangzhou Shipyard International Company Limited for the construction of four high-specification, ECO, ice class 1A MR Product Tankers to be delivered between June 2029 and March 2030.
Pentagon plans for a new Autonomous Warfare Command and Project Agincourt highlight growing U.S. defense focus on drones, AI, autonomous systems and resilient power infrastructure
An analysis of executives at FTSE-listed companies and more than 322,000 UK Biobank participants finds lower leadership attainment among ethnic Chinese men
Expanded Portfolio Addresses Demand for Secure, High-Throughput Communications Across Swarm-Scale Unmanned Operations
Deployment on Google Cloud Platform is designed to enhance computational capacity, data governance and operational flexibility as MitoCareX advances its drug discovery programs
Deployment on Google Cloud Platform is designed to enhance computational capacity, data governance and operational flexibility as MitoCareX advances its drug discovery programs
Irvine and Los Angeles, CA, Oct. 07, 2026 (GLOBE NEWSWIRE) — Aperture AC (NASDAQ: APUR), a special purpose acquisition company (“Aperture”), and Atlantic HPC Group Inc (“Atlantic”), a U.S.-based digital infrastructure company that develops and operates power-intensive bitcoin mining and computing facilities across Oklahoma, Arkansas, Ohio and following the Valley Oasis acquisition, Tennessee, today announced that the board of directors of Atlantic has appointed Leo Lin as Atlantic’s Chief Executive Officer, effective October 1, 2026. Lin is a seasoned executive with over 20 years of experience in helping companies scale their operations and achieve rapid growth. Lin succeeds Jacqueline Jiang, who has stepped down as Chief Executive Officer and will continue to serve as a member of Atlantic’s board of directors.
Irvine and Los Angeles, CA, Oct. 07, 2026 (GLOBE NEWSWIRE) — Aperture AC (NASDAQ: APUR), a special purpose acquisition company (“Aperture”), and Atlantic HPC Group Inc (“Atlantic”), a U.S.-based digital infrastructure company that develops and operates power-intensive bitcoin mining and computing facilities across Oklahoma, Arkansas, Ohio and following the Valley Oasis acquisition, Tennessee, today announced that the board of directors of Atlantic has appointed Leo Lin as Atlantic’s Chief Executive Officer, effective October 1, 2026. Lin is a seasoned executive with over 20 years of experience in helping companies scale their operations and achieve rapid growth. Lin succeeds Jacqueline Jiang, who has stepped down as Chief Executive Officer and will continue to serve as a member of Atlantic’s board of directors.
Transaction streamlines business and sharpens focus on core betting, gaming, and media priorities
LONDON – 7 October 2026 — CHARM Therapeutics (“CHARM”, “The Company”), a clinical-stage biotechnology company addressing resistance in acute myeloid leukemia (AML) with a best-in-class menin inhibitor, today announces it has initiated dosing and fully enrolled the first cohort in its Phase I/II clinical trial of CHM-029 in patients with AML. This is the first example of a molecule designed using a protein-ligand co-folding model to progress into clinical studies.